Research Article| Volume 18, ISSUE 1, P95-105, January 1996

Steady-state bioavailability of controlled-release oxycodone in normal subjects

      This paper is only available as a PDF. To read, Please Download here.


      The steady-state bioavailability of a controlled-release (CR) oxycodone tablet was compared with that of an immediate-release (IR) oxycodone solution in a randomized, analytically masked, multiple-dose, crossover study in 24 normal subjects. Each subject received either one 10-mg CR oxycodone tablet every 12 hours for 4 days or 5 mL of a 1-mg/1 mL IR oxycodone solution every 6 hours for 4 days. Steady state was achieved after approximately 1 day of dosing. The mean (±SD) maximum plasma oxycodone concentrations for CR oxycodone and IR oxycodone were 15.1 ± 4.7 ng/mL and 15.6 ± 4.4 ng/mL, respectively. The time to maximum concentration (Tmax) was approximately twice as long for CR oxycodone (3.2 ± 2.2 hours) as for IR oxycodone (1.4 ± 0.7 hours) (P = 0.005). The area under the plasma concentation—time curve from 0 to 12 hours at steady state was 103.6 ± 40.0 ng • h/mL for CR oxycodone and 99.0 ± 35.8 ng • h/mL for IR oxycodone. Except for Tmax, there were no significant differences in pharmacokinetic parameters between treatments. Approximately twice as many adverse experiences, several of longer duration than noted with CR oxycodone, were reported with IR oxycodone. The bioavailability of the CR tablet was equal to that of the IR solution; however, the rate of oxycodone absorption from the CR tablet was slower than that from the IR solution, as shown by the Tmax value. The use of CR oxycodone will allow selection of the most clinically appropriate nonopioid analgesic, as well as independent titration and dosing, thereby enhancing therapeutic flexibility.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Houde RW
        The use and misuse of narcotics in the treatment of chronic pain.
        Adv Neurol. 1974; 4: 527-536
        • Beaver WT
        • Wallenstein SL
        • Rogers A
        • Houde RW
        Analgesic studies of codeine and oxycodone in patients with cancer II. Comparisons of intramuscular oxycodone with intramuscular morphine and codeine.
        J Pharmacol Exp Ther. 1978; 207: 101-108
        • Pöyhiä R
        • Vainio A
        • Kalso E
        A review of oxycodone's clinical pharmacokinetics and pharmacodynamics.
        J Pain Symptom Manage. 1993; 8: 63-66
        • Pöyhiä R
        • Seppälä T
        • Olkkola KT
        • Kalso E
        The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects.
        Br J Clin Pharmacol. 1992; 33: 617-621
        • Leow KP
        • Smith MT
        • Williams B
        • Cramond T
        Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer.
        Clin Pharmacol Ther. 1992; 52: 487-495
        • Kalso E
        • Vainio A
        Morphine and oxycodone hydrochloride in the management of cancer pain.
        Clin Pharmacol Ther. 1990; 47: 639-646
        • Kantor TG
        • Hopper M
        • Laska E
        Adverse effects of commonly ordered oral narcotics.
        J Clin Pharmacol. 1981; 21: 1-8
        • Kaiko RF
        • Benziger DP
        • Fitzmartin RD
        • et al.
        Pharmacokinetic/pharmacodynamic relationships of controlled-release oxycodone.
        Clin Pharmacol Ther. 1996; 59: 52-61
        • Gourlay GK
        • Plummer JL
        • Cherry DA
        Chronopharmacokinetic variability in plasma morphine concentrations of following oral doses of morphine solution.
        Pain. 1995; 61: 375-381
        • Lacouture PG
        • Slagle NS
        • Iwan T
        • et al.
        Pain intensity fluctuation: The effect of controlled-release (CR) opiate every 12 hours around-the-clock vs. prn dosing..
        Poster presented at the 13th Annual Meeting of the American Pain Society. 10131994; (Miami Beach, Fla)
        • Gourlay GK
        • Plummer JL
        • Cherry DA
        • Onley MM
        A comparison of Kapanol (a new sustained-release morphine formulation), MST Continus, and morphine solution in cancer patients: Pharmacokinetic aspects of morphine and morphine metabolites.
        in: Gebhart GF Hammond DL Jensen TS Proceedings of the 7th World Congress on Pain. IASP Press, Seattle, Wash1994: 631-643